The moderate to severe Crohn’s disease (CD) therapy market presents an attractive commercial opportunity for new, effective treatments. Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., Remicade, Humira) have advanced the treatment of moderate to severe CD by offering improved efficacy over conventional therapies; however, these agents still have safety risks and efficacy limitations. Novel biological agents with non-TNF inhibitor mechanisms of action (i.e., Takeda’s Entyvio, approved in 2014, and Janssen’s Stelara, approved in 2016) have expanded the treatment options for moderate to severe CD, but significant needs remain, especially for patients refractory to available therapies.
- What are the treatment drivers and goals for moderate to severe CD?
- What drug attributes are key influencers on physician prescribing behavior, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe CD?
- What are the prevailing areas of unmet need and opportunity in moderate to severe CD?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new CD drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European gastroenterologists fielded in December 2017 and January 2018
Key companies: AbbVie, Galapagos NV, Gilead, Janssen, Merck, Takeda, TiGenix
Key drugs: Humira, Remicade, Stelara, Entyvio, Filgotinib, Cx-601, Risankizumab